The purpose of this study was to investigate the antidiabetic activity of extracts from leaves of Physalis peruviana L. used in the Eastern part of the Democratic Republic of the Congo used against diabetes. Different fractions with hexane, ethyl acetate and residue were obtained from the hydroalcoholic extract of Physalis peruviana leaves. The antidiabetic evaluation of hydroalcoholic and its fractions was evaluated in diabetic rats by a single administration of streptozotocin (50 mg/kg body weight) intravenously. The Reference group received glibenclamide (6.5 mg/kg body weight) and each test group received 100 mg/kg of body weight. Those groups were compared with a control group which received only a Tween 20 solution (1 ml per 100 g body weight). Serum biochemical profiles were evaluated by some blood markers including serum glucose, serum alanine transaminase (ALT), serum aspartate transaminase (AST) serum creatinine, total protein, triglyceride, total cholesterol, HDL-cholesterol and LDL-cholesterol. Antidiabetic profile evaluation showed no significant variation (P < 0.05) in blood glucose between groups after 28 days of treatment. There was no significant difference in the biochemical markers change including creatinine, ALT, AST, total protein, triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol. The hydroalcoholic extract from the leaves of Physalis peruviana L. and its fractions showed antidiabetic activity suggesting future detailed studies for new chemical entities lead drug discovery.